XFOR

X4 PHARMACEUTICALS INC

XFOR·98420X202·US·Common Stock·Healthcare - Biotechnology-Activist

XFOR (X4 PHARMACEUTICALS INC) is held by 45 institutional investors as of Q1 2026. Largest holders: MORGAN STANLEY ($39.1M), FMR LLC ($33.5M), VANGUARD CAPITAL MANAGEMENT LLC ($14.4M). Net institutional sentiment: Mixed.

45
Holders
Avg rating(9 Elite)
$134M
Total Value
51% (51)
Fund Consensus
22 buying - 21 selling
XFORSmart Money Verdict
View all
Held by 45 funds
9 elite
Who's Trading
ActivistPAPerceptive Advisors LLC7.3%May 15, 2026
InsiderKDKIRSKE DAVIDSell $73KMay 12, 2026
ActivistMorgan StanleyMorgan Stanley10.2%Mar 6, 2026
ActivistBVBIOTECHNOLOGY VALUE FUND L P2.1%Feb 17, 2026
ActivistSVSaturn V Capital Management LP7.4%Feb 17, 2026
ActivistBLBain Capital Life Sciences Fund, L.P.0.0%Feb 17, 2026
ActivistTETrails Edge Capital Partners, LP5.8%Feb 17, 2026
ActivistNANantahala Capital Management, LLC2.8%Feb 13, 2026
InsiderCRCraig Adam RBuy $250KOct 23, 2025
InsiderBMBaldry MarkBuy $3KMay 16, 2025
13F: Insider & Congress:
Fund
Action
Shares
Value
Weight
Est. P&L
Conviction
Increased
9.5M(+15.3%)$39.1M0.0%+8.74%
33
Decreased
8.1M(-4.7%)$33.5M0.0%+6.01%
0
New
3.5M$14.4M0.0%+32.43%
39
Unchanged
2.7M$11.1M0.0%+6.01%
0
Decreased
1.2M(-1.2%)$5M0.0%-14.31%
0
Increased
1.2M(+2062.5%)$5M0.0%-13.85%
43
Increased
1M(+0.0%)$4.1M0.0%+6.01%
27
Decreased
939,726(-0.1%)$3.9M0.0%-33.49%
0
Increased
882,134(+6.0%)$3.6M0.0%+7.23%
28
Increased
856,222(+3768.2%)$3.5M0.0%+31.58%
43
New
480,733$2M0.0%+32.43%
36
Increased
403,534(+103.6%)$1.7M0.0%-1.61%
41
Increased
336,834(+318.7%)$1.4M0.0%+24.99%
41
Increased
267,340(+6374.7%)$1.1M0.0%+29.43%
41
Increased
218,954(+223.2%)$904,2800.0%+22.95%
40
Unchanged
178,235$736,1110.0%+6.01%
0
Increased
150,676(+321.3%)$622,2920.0%-26.42%
27
New
127,321$525,8360.0%+32.43%
33
Decreased
66,749(-0.1%)$275,6730.0%+6.01%
0
Decreased
57,300(-47.5%)$236,6490.0%+6.01%
0

Showing 1-20 of 51

1 / 3

Other Healthcare stocks held by institutions

Data sourced from four SEC data sources: 13F, Form 4, 13D/13G, and STOCK Act. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used